KaydedilenlerDerginizi ekleyin

Dergiler / İzmir Tepecik Eğitim Hastanesi Dergisi / 2018 / Cilt: 28 - Sayı: 3

The correlation between neutrophil - lymphocyte ratio and neoadjuvant chemoradiotherapy response prediction in locally advanced rectal cancer

Lokal ileri evre rektum kanserinde nötrofil lenfosit oranı ile neoadjuvan kemoradyoterapiye yanıtın ilişkisi

Veysel KARAHAN
Mehmet ÜSTÜN
Levent UĞURLU
Tayfun KAYA
Mustafa EMİROĞLU
CENGİZ AYDIN
Sayfa
163–168
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: NLR can be used as a predictive factor in locally advanced rectal cancer before initiating neoadjuvant chemoradiotherapy.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The determination of predictive factors for neoadjuvant chemoradiotherapy response in locally advanced rectum cancer is critical concerning treatment management.
📊
Temel Bulgular & Veri:Methods: Fifty patients who were diagnosed with locally advanced rectum cancer without distant metastasis and underwent surgery after the neoadjuvant CRT treatment in the department of general surgery, between January 2008-2015 were analyzed.
💡
Sonuç & Katkı:Conclusion: NLR can be used as a predictive factor in locally advanced rectal cancer before initiating neoadjuvant chemoradiotherapy.
🔬Tür:Araştırma Makalesi
📍Kapsam:2008-2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: The determination of predictive factors for neoadjuvant chemoradiotherapy response in locally advanced rectum cancer is critical concerning treatment management. We aim to analyze the predictive value of clinicopathologic findings of locally advanced rectal cancer patients before neoadjuvant chemoradiotherapy. Methods: Fifty patients who were diagnosed with locally advanced rectum cancer without distant metastasis and underwent surgery after the neoadjuvant CRT treatment in the department of general surgery, between January 2008-2015 were analyzed. Results: Twenty three (46%) cases did not yield pathologic response, while 27 (54%) responded to neoadjuvant chemoradiotherapy. There was no statistically significant difference between the responding, and the non-responding groups in terms of mean ages and gender distribution (p=0.360, p=0.665), the distribution of tumor distance from anal verge (p=0.777), pathologic types (p=0.451), pre-op T stage and N stage (p=0.322 and p=0.321), type of surgical procedures (p=0.061, p=0.200), levels of CEA (p=0.195), and PLR (p=0.704). The possiblity of not responding in cases with NLR> 4 was statistically significantly different from those with NLR <4 (95% Confidence Interval: 2.043-62.915) compared to NLR <4 cases (p=0.005). Conclusion: NLR can be used as a predictive factor in locally advanced rectal cancer before initiating neoadjuvant chemoradiotherapy.

Abstract

Amaç: Lokal ileri evre rektal kanserde neoadjuvan kemoradyoterapi yanıtı için öngörülen faktörlerin belirlenmesi tedavi yönetimi açısından çok önemlidir. Neoadjuvan kemoradyoterapi öncesi lokal ileri evre rektal kanser hastalarının klinikopatolojik bulgularının öngörülen değerini araştırmayı amaçladık. Yöntem: Ocak 2008-2015 tarihleri arasında neoadjuvan KRT tedavisinden sonra opere edilen, uzak metastazı olmayan, lokal ileri evre rektum kanseri tanısı konan hastalar geriye dönük olarak incelendi. Bulgular: Olguların 23’ü (%46) patolojik yanıt vermezken, 27’si (%54) neoadjuvan kemoradyoterapiye yanıt vermiştir. Yanıt veren grup ile yanıtsız grup arasında yaş ortalamaları ve cinsiyet dağılımı (p=0,360, p=0,665), tümörün anal çizgiden mesafesinin dağılımı (p=0,777), patolojik tiplerin dağılımı (p=0,451), pre-op T evre ve N evre (p=0,322 ve p=0,321), cerrahi prosedür tipi (p=0,061, p=0,200), CEA düzeyi (p=0,195), PLO düzeyi (p=0,704) açısından istatistiksel olarak anlamlı fark saptanmadı. NLO> 4 saptanan olgularda yanıt vermeme olasılığı NLO <4 olanlara göre istatistiksel olarak anlamlı derecede farklıydı (%95 güven aralığı: 2,043-62,915) (p=0,005). Sonuç: Neoadjuvan kemoradyoterapi öncesi NLO lokal ileri evre rektal kanserde öngörülen bir faktör olarak kullanılabilir.

🔖

Bu Makaleye Atıf Yap

KARAHAN, V., ÜSTÜN, M., UĞURLU, L., KAYA, T., EMİROĞLU, M., AYDIN, C. (2018). The correlation between neutrophil - lymphocyte ratio and neoadjuvant chemoradiotherapy response prediction in locally advanced rectal cancer. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 28 - Sayı: 3, 163–168. https://ajindex.com/articles/198686

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-40. https://doi.org/10.1056/NEJMoa040694.
  2. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, ClosonDejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006; 24:4620-25. https://doi.org/10.1200/JCO.2006.06.7629
  3. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracilbased chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25:4379-86. https://doi.org/10.1200/JCO.2007.11.9685
  4. Maas M, Nelemans PJ, Valentini V, Crane CH, Capirci C, Rodel C, et al. Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients. Int J Cancer. 2015;137:212-20. https://doi.org/10.1002/ijc.29355
  5. Govindarajan A, Reidy D, Weiser MR, Paty PB, Temple LK, Guillem JG, et al. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision. Ann Surg Oncol. 2011;18:3666-72. https://doi.org/10.1245/s10434-011-1788-y McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223-6. https://doi.org/10.1097/MCO.0b013e32832a7902
  6. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633-41. https://doi.org/10.1016/j.ejca.2011.03.028
  7. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammationbased pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg. 2009;249:788-93. https://doi.org/10.1097/SLA.0b013e3181a3e738
  8. Roxburgh C, McDonald A, Salmond J, Oien K, Anderson J, McKee R et al. Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. Int J Colorectal Dis. 2011;26:483-92. https://doi.org/10.1007/s0038